20324-49-6

Basic information

• Product Name: 4-Chloro-2-mercaptobenzoic acid
• Synonyms: 4-Chloro-2-mercaptobenzoic acid;Benzoic acid, 4-chloro-2-Mercapto-
• CAS NO: 20324-49-6
• Molecular Formula: C₇H₅ClO₂S
• Molecular Weight: 188.63
• Mol File: 20324-49-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 195-196 °C
• Boiling Point: 334.0±27.0 °C(Predicted)
• Appearance: /
• Density: 1.490±0.06 g/cm3(Predicted)
• PKA: 3.31±0.36(Predicted)
• CAS DataBase Reference: 4-Chloro-2-mercaptobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-2-mercaptobenzoic acid(20324-49-6)
• EPA Substance Registry System: 4-Chloro-2-mercaptobenzoic acid(20324-49-6)

Safety Data

• Hazardous Substances Data: 20324-49-6(Hazardous Substances Data)

Usage

General Description

4-Chloro-2-mercaptobenzoic acid is a chemical compound with the molecular formula C7H5ClO2S. It is a derivative of benzoic acid and contains a chlorine atom and a thiol group on the benzene ring. 4-Chloro-2-mercaptobenzoic acid is used in organic synthesis as a reagent for the preparation of various compounds. It is also used in the pharmaceutical industry for the synthesis of new drugs. Additionally, it has potential applications in the field of materials science, specifically in the development of functional materials and polymers. However, it is important to handle this compound with care as it is toxic and can cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 140-89-6 potassium ethyl xanthogenate 

Downstream Products

• 40183-35-5 2-(benzylthio)-4-chlorobenzoic acid 
• 52948-12-6 Methyl 4-chloro-2-mercaptobenzoate 
• 6086-80-2 6-chloro-1-(2-diethylamino-ethylamino)-4-methyl-thioxanthen-9-one 
• 40183-46-8 4'-Chlor-2'-mercaptoacetophenon 
• 40183-39-9 2'-(Benzylthio)-4'-chloracetophenon 
• 120121-37-1 4-chloro-2-(hydroxymethyl)thiophenol 
• 19993-66-9 4,4'-dichloro-2,2'-disulfanediyl-bis-benzoyl chloride 

Relevant articles and documents

Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor

Ziresovir (RO-0529, AK0529) is reported here for the first time as a promising respiratory syncytial virus (RSV) fusion (F) protein inhibitor that currently is in phase 2 clinical trials. This article describes the process of RO-0529 as a potent, selective, and orally bioavailable RSV F protein inhibitor and highlights the in vitro and in vivo anti-RSV activities and pharmacokinetics in animal species. RO-0529 demonstrates single-digit nM EC50 potency against laboratory strains, as well as clinical isolates of RSV in cellular assays, and more than one log viral load reduction in BALB/c mouse model of RSV viral infection. RO-0529 was proven to be a specific RSV F protein inhibitor by identification of drug resistant mutations of D486N, D489V, and D489Y in RSV F protein and the inhibition of RSV F protein-induced cell-cell fusion in cellular assays.

Novel inhibitors of the prenylated protein methyltransferase reveal distinctive structural requirements

Inhibitors of a prenylated protein methyltransferase were synthesized and evaluated. S-farnesyl-5-fluorothiosalicylic acid and the 5-chloro analog (but not the 4-fluoro, 4-chloro or 3-chloro analogs) were potent inhibitors, as was the parent compound S-farnesyl thiosalicylic acid (FTS), whose methyl ester was far less active. S-geranyl and S-geranylgeranyl thiosalicylic acids were more than ten times less potent than FTS.